A Westlake University team disclosed a high-throughput engineering platform aimed at creating fast-acting covalent protein therapeutics. The approach, published in Science, describes a selection system designed to identify covalent binders with rapid functional effects. The platform—led by principal investigators Bobo Dang and Ting Zhou at Westlake Laboratory—targets a practical bottleneck in covalent biologics: scaling the design and screening of candidates efficiently while preserving the desired speed and specificity of covalent engagement. The report signals a push toward next-generation biologics that combine potency with temporal control, potentially expanding covalent chemistry use beyond traditional small-molecule settings.